Literature DB >> 31488454

POD24 in MZL: a means to an end or an end point in itself?

Matthew J Maurer1.   

Abstract

Mesh：

Year:  2019        PMID： 31488454      PMCID： PMC6729009          DOI： 10.1182/blood.2019002305

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.

Authors:  Ciara L Freeman; Robert Kridel; Alden A Moccia; Kerry J Savage; Diego R Villa; David W Scott; Alina S Gerrie; David Ferguson; Fergus Cafferty; Graham W Slack; Pedro Farinha; Brian Skinnider; Joseph M Connors; Laurie H Sehn
Journal:  Blood       Date:  2019-07-12       Impact factor: 22.113

2.  Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.

Authors:  Stefano Luminari; Michele Merli; Sara Rattotti; Vittoria Tarantino; Luigi Marcheselli; Federica Cavallo; Marzia Varettoni; Benedetta Bianchi; Francesco Merli; Alessandra Tedeschi; Giuseppina Cabras; Francesca Re; Carlo Visco; Marcia Torresan Delamain; Emanuele Cencini; Michele Spina; Simone Ferrero; Angela Ferrari; Marina Deodato; Donato Mannina; Ombretta Annibali; Angela Rago; Lorella Orsucci; Irene Defrancesco; Marco Frigeni; Marina Cesaretti; Luca Arcaini
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

3.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors:  Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

4.  The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas.

Authors:  Sean I Tracy; Melissa C Larson; Andrew L Feldman; Matthew J Maurer; Anne J Novak; Susan L Slager; Jose C Villasboas; Cristine Allmer; Thomas M Habermann; Umar Farooq; Sergei Syrbu; James R Cerhan; Brian K Link
Journal:  Am J Hematol       Date:  2019-04-10       Impact factor: 10.047

5.  A MALT lymphoma prognostic index.

Authors:  Catherine Thieblemont; Luciano Cascione; Annarita Conconi; Barbara Kiesewetter; Markus Raderer; Gianluca Gaidano; Maurizio Martelli; Daniele Laszlo; Bertrand Coiffier; Armando Lopez Guillermo; Valter Torri; Franco Cavalli; Peter W Johnson; Emanuele Zucca
Journal:  Blood       Date:  2017-07-18       Impact factor: 22.113

6.  Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.

Authors:  Clémentine Sarkozy; Matthew J Maurer; Brian K Link; Hervé Ghesquieres; Emmanuelle Nicolas; Carrie A Thompson; Alexandra Traverse-Glehen; Andrew L Feldman; Cristine Allmer; Susan L Slager; Stephen M Ansell; Thomas M Habermann; Emmanuel Bachy; James R Cerhan; Gilles Salles
Journal:  J Clin Oncol       Date:  2018-11-27       Impact factor: 44.544

7.  Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.

Authors:  Matthew J Maurer; Emmanuel Bachy; Hervé Ghesquières; Stephen M Ansell; Grzegorz S Nowakowski; Carrie A Thompson; David J Inwards; Cristine Allmer; Catherine Chassagne-Clément; Emmanuelle Nicolas-Virelizier; Catherine Sebban; Laure Lebras; Clementine Sarkozy; William R Macon; Andrew L Feldman; Sergei I Syrbu; Alexandra Traverse-Glehan; Bertrand Coiffier; Susan L Slager; George J Weiner; Thomas E Witzig; Thomas M Habermann; Gilles Salles; James R Cerhan; Brian K Link
Journal:  Am J Hematol       Date:  2016-09-03       Impact factor: 10.047

8.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

9.  Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Authors:  John F Seymour; Robert Marcus; Andrew Davies; Eve Gallop-Evans; Andrew Grigg; Andrew Haynes; Michael Herold; Thomas Illmer; Herman Nilsson-Ehle; Martin Sökler; Ulrich Dünzinger; Tina Nielsen; Aino Launonen; Wolfgang Hiddemann
Journal:  Haematologica       Date:  2018-12-20       Impact factor: 9.941
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.